Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/54/f0/ac/54f0ac5d-ba46-f9e7-28b7-672ab0a048c7/mza_5551349009705862383.jpg/600x600bb.jpg

ReachMD CME

ReachMD

387 episodes

1 day ago

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Science

Medicine

RSS

All content for ReachMD CME is the property of ReachMD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

Medicine

Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia

ReachMD CME

14 minutes 15 seconds

2 months ago

Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia

CME credits: 0.25
Valid until: 30-10-2026
Claim your CME credit at https://reachmd.com/programs/cme/are-all-vmat2s-the-same-data-driven-treatment-decisions-for-tardive-dyskinesia/36174/

Tardive Dyskinesia (TD) is an involuntary movement disorder that can develop as a side effect of taking antipsychotic and other medications. Currently there are 2 FDA approved VMAT2 inhibitors for treating TD. Join Drs. Cristoph U. Correll and Jonathan M. Meyer for this expert discussion on the most recent data presented at the Psych Congress 2025 in San Diego on VMAT2 inhibitors for the treatment of TD.